EGFR and head and neck squamous cell carcinoma: Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody, was the first molecular-targeted drug approved by the U.S. Food and Drug Administration (FDA) as a chemotherapeutic agent for HNSCC in 2006 [5,16].